AGEN
Price
$3.82
Change
+$0.16 (+4.37%)
Updated
May 23 closing price
Capitalization
104.73M
CHRS
Price
$0.76
Change
-$0.01 (-1.30%)
Updated
May 23 closing price
Capitalization
87.66M
68 days until earnings call
Interact to see
Advertisement

AGEN vs CHRS

Header iconAGEN vs CHRS Comparison
Open Charts AGEN vs CHRSBanner chart's image
Agenus
Price$3.82
Change+$0.16 (+4.37%)
Volume$423.01K
Capitalization104.73M
Coherus BioSciences
Price$0.76
Change-$0.01 (-1.30%)
Volume$1.21M
Capitalization87.66M
AGEN vs CHRS Comparison Chart
Loading...
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGEN vs. CHRS commentary
May 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGEN is a Hold and CHRS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 25, 2025
Stock price -- (AGEN: $3.82 vs. CHRS: $0.76)
Brand notoriety: AGEN and CHRS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGEN: 60% vs. CHRS: 66%
Market capitalization -- AGEN: $104.73M vs. CHRS: $87.66M
AGEN [@Biotechnology] is valued at $104.73M. CHRS’s [@Biotechnology] market capitalization is $87.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $298.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGEN’s FA Score shows that 0 FA rating(s) are green whileCHRS’s FA Score has 0 green FA rating(s).

  • AGEN’s FA Score: 0 green, 5 red.
  • CHRS’s FA Score: 0 green, 5 red.
According to our system of comparison, AGEN is a better buy in the long-term than CHRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGEN’s TA Score shows that 4 TA indicator(s) are bullish while CHRS’s TA Score has 3 bullish TA indicator(s).

  • AGEN’s TA Score: 4 bullish, 4 bearish.
  • CHRS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, AGEN is a better buy in the short-term than CHRS.

Price Growth

AGEN (@Biotechnology) experienced а +9.77% price change this week, while CHRS (@Biotechnology) price change was -0.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.22%. For the same industry, the average monthly price growth was +3.23%, and the average quarterly price growth was -2.73%.

Reported Earning Dates

AGEN is expected to report earnings on Mar 17, 2025.

CHRS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AGEN($105M) has a higher market cap than CHRS($87.7M). CHRS has higher P/E ratio than AGEN: CHRS (1.72) vs AGEN (0.13). AGEN YTD gains are higher at: 39.416 vs. CHRS (-45.210). CHRS has higher annual earnings (EBITDA): 37.3M vs. AGEN (-77.64M). CHRS has more cash in the bank: 97.7M vs. AGEN (44.8M). AGEN has less debt than CHRS: AGEN (78.4M) vs CHRS (270M). CHRS has higher revenues than AGEN: CHRS (304M) vs AGEN (160M).
AGENCHRSAGEN / CHRS
Capitalization105M87.7M120%
EBITDA-77.64M37.3M-208%
Gain YTD39.416-45.210-87%
P/E Ratio0.131.728%
Revenue160M304M53%
Total Cash44.8M97.7M46%
Total Debt78.4M270M29%
FUNDAMENTALS RATINGS
AGEN vs CHRS: Fundamental Ratings
AGEN
CHRS
OUTLOOK RATING
1..100
1556
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
90
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4492
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CHRS's Valuation (90) in the Biotechnology industry is in the same range as AGEN (96). This means that CHRS’s stock grew similarly to AGEN’s over the last 12 months.

CHRS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AGEN (100). This means that CHRS’s stock grew similarly to AGEN’s over the last 12 months.

CHRS's SMR Rating (100) in the Biotechnology industry is in the same range as AGEN (100). This means that CHRS’s stock grew similarly to AGEN’s over the last 12 months.

AGEN's Price Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for CHRS (92). This means that AGEN’s stock grew somewhat faster than CHRS’s over the last 12 months.

CHRS's P/E Growth Rating (97) in the Biotechnology industry is in the same range as AGEN (100). This means that CHRS’s stock grew similarly to AGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGENCHRS
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 5 days ago
72%
Declines
ODDS (%)
Bearish Trend 18 days ago
89%
Bearish Trend 9 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WJRYY21.580.21
+0.97%
West Japan Railway Co.
MGPHF0.04N/A
+0.25%
Mason Resources Inc.
ABBNY57.00-0.14
-0.25%
ABB Ltd.
ANYYY26.93-0.36
-1.31%
Aena SME S.A.
TCNNF4.19-0.07
-1.64%
Trulieve Cannabis Corporation